One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Gastrointestinal Therapeutics Market

[ 英語タイトル ] Gastrointestinal Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089023
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 113
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Abbott Laboratories
- Abbvie (Allergan PLC)
- Astellas Pharma Inc.
- AstraZeneca
- Bayer AG
- GlaxoSmithKline PLC
- Janssen Pharmaceuticals Inc. (Johnson & Johnson)
- Pfizer Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited

[Report Description]

The gastrointestinal therapeutics market is expected to register a healthy CAGR of nearly 6.5 % during the forecast period. The major factors that contribute to the growth of the gastrointestinal therapeutics market include the increasing prevalence of gastrointestinal diseases due to unhealthy dietary habits, additional numbers of clinical trials with accurate results, increasing healthcare expenditure, and growth in the geriatric population.

According to the National Health Interview Survey (2017), 15.3 million adults were diagnosed with ulcers in the United States. Therefore a wide range of new generation therapeutics is found targeting that include novel small molecules and cellular therapy are currently under investigation. Other driving factors include the rising surgical treatments and hospitalizations, due to GI diseases, and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars.

However, risk factors, such as those related to the physiological, behavioral, psychosocial, and socio-environmental aspects, restrict the populations from reporting the diseases early, which reflects the low awareness and the economic burden. These risk factors and the increasing number of patent expirations restrict the growth of the gastrointestinal therapeutics market.

Key Market Trends

Ulcerative Colitis is Found to Witness Healthy CAGR Over the Forecast Period

Ulcerative colitis is found to witness rapid growth in the gastrointestinal therapeutics market. The growth of this segment can be attributed to the easy availability of drugs in the market to treat this condition. The segment is also anticipated to grow at a considerable rate owing to high clinical urgency to curb the growing prevalence of ulcerative colitis. This high prevalence is due to poor prognosis and consumption of unhealthy food, which may result in a high probability of disease recurrence. In addition, Takeda Pharmaceuticals, Jassen Pharmaceuticals, and Pfizer are among the major global companies that have established themselves with their products for the treatment of inflammatory ulcerative colitis.

Asia-Pacific is the Fastest Growing Region in the Gastrointestinal Therapeutics Market

In recent years, the Asian countries have been witnessing a similar growth trend to that of the western developed markets, particularly owing to the increasing economic growth, along with the privatization, competitive site experience, technological expertise, infrastructure, and the scale to manage large-scale clinical trials across India, China, Japan, South Korea, and other countries. The unmet medical need and potential market opportunity have accelerated the partnerships between major global companies and Asian pharmaceutical companies, for the development and exploration of commercial potential in the growth of the pharmaceutical business.

The North America market has also been accounted for the largest share and is expected to maintain its position during the forecast period. This substantial share can be attributed to unprecedented change in lifestyle, resulting in greater incidence of gastrointestinal diseases.

Competitive Landscape

The major players in the gastrointestinal therapeutics market include Abbott, Allergan, GlaxoSmithKline PLC, Pfizer, and Takeda Pharmaceutical Company Limited, among others. These key players have extensively employed competition sustainability strategies such as new product development and regional and distribution channel expansion to gain a higher share in the market. Moreover, increased focus on refining operation and supply chain management has facilitated key players to maintain a competitive edge.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of GI Diseases
4.2.2 Rising Investments in R&D by Pharmaceutical Companies
4.3 Market Restraints
4.3.1 Rising Socio-economic Burden Associated with Gastrointestinal Disorders
4.3.2 Increasing Number of Patent Expiries
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Drug Type
5.1.1 Antacids
5.1.2 Laxatives
5.1.3 Antidiarrheal agents
5.1.4 Antiemetics
5.1.5 Antiulcer agents
5.1.6 Other Drug Types
5.2 Dosage Form
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Other Dosage Forms
5.3 Application
5.3.1 Ulcerative Colitis
5.3.2 Irritable Bowel Syndrome
5.3.3 Crohn's Disease
5.3.4 Celiac Disease
5.3.5 Gastroenteritis
5.3.6 Other Applications
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Abbvie (Allergan PLC)
6.1.3 Astellas Pharma Inc.
6.1.4 AstraZeneca
6.1.5 Bayer AG
6.1.6 GlaxoSmithKline PLC
6.1.7 Janssen Pharmaceuticals Inc. (Johnson & Johnson)
6.1.8 Pfizer Inc.
6.1.9 AbbVie Inc.
6.1.10 Takeda Pharmaceutical Company Limited




Recommended reports